tbuckley/cabot-search huggingface dataset:
Changes in the age of breast cancer diagnosis along the last century in Argentina
Authors: L. Koliren, P. Micone, S. Otero, M. Bianconi, C. Benavente, L. Rafailovici, A. Zoricomba, M. Filomia, D. Perez, G. Jankilevich
Journal: Journal of Clinical Oncology (2005)

875 Background: The age of breast cancer (BC) onset seems to have decreased during the last century in Buenos Aires.To validate this trend we tripled the number of patients(pts),including other Argentine oncology centers. Methods: We performed a multicenter,retrospective,observational study.The clinical records of 6063 pst with BC diagnosis,born between 1900 and 1980 were reviewed.The population was divided in to three groups(G). Born between 1900 and 1930 (GA),1931 and 1960(GB) and after GC.The following variables were evaluated: birth decade,age at initial disease diagnosis,number of pts ≤ 40 years in the three groups. The T-Student Test was used for independent variables for age analysis., the square Chi Test to determine the rate of pts ≤ 40 years and the Estadistica 6.0 Program for data analysis. Results: The average age of populations was 57 (± 13 years). GA included 2371 pts with a mean age of 69 (± 9 years), GB 3439 pts with a mean age of 53 (± 9 years) and GC 253 pts with a mean age of 35 (± 4 years).(GA vs. GB p< 0.001). The pts who were≤ 40 years represented 9% of total population (543 pts) and were distributed in the following manner:GA 21 pts (0,9%),GB 286 pts (8%) and GC 236 pts (93%). GA vs GB p< 0.01. Conclusions: 1-A 16-year decrease in the age of BC diagnosis was confirmed among pts born between 1931 and 1960 with the respect to those born before, 2-in GB the number of pts who were ≤ 40 years old increased almost ten times with respect to GA. 3-We believe tha early diagnosis, a better access to health services, environmental changes and life style have had a significant impact on results. No significant financial relationships to disclose.
Guillain Barré syndrome, a possible side effect of buffy coat transfusion and IFN a therapy in relapsed CML after bone marrow transplantation
Authors: A. Schwarzer, E. Schulze, S. Leiblein, R. Krahl, M. Kubel, C. Bartram, J. Edelmann, U. Sack, W. Helbig
Journal: Annals of Oncology (1995)
Osteopontin and basic fibroblast growth factor are associated with prognosis in advanced non-small cell lung cancer (JMTO LC 0004)
Authors: T. Kawaguchi, S. Isa, S. Teramukai, K. Minato, M. Fukushima, M. Kawahara, K. Furuse, P. C. Mack
Journal: Journal of Clinical Oncology (2008)

19025 Background: A prospective randomized phase III trial for advanced non-small cell lung cancer (NSCLC) compared paclitaxel (P) plus carboplatin (C) vs. vinorelbine (V), gemcitabine (G) followed by docetaxel (D) in the Japan-Multinational Trial Organization (JMTO LC0003) (Kawahara ASCO 06). This trial was conducted jointly with SWOG 0003 using a common arm of PC. Pharmacogenomic studies of samples from both trials demonstrated significant associations between genotype and clinical outcome (Gandara ASCO 07). Previous analysis of SWOG 0003 samples showed that elevated osteopontin (OPN) plasma levels were highly prognostic (Mack ASCO 05). Our correlative study (JMTO LC 0004) of JMTO LC 0003 was originally designed to assess β-tubulin mutations, which was determined to be insignificant. We elected to study and validate OPN as a prognostic marker, using stock samples under additional approval of JMTO IRB. Method: A total of 20 ml of blood was collected prior to treatment from patients enrolled in JMTO LC0003. Serum concentrations of OPN and basic fibroblast growth factor (bFGF) were measured by ELISA. The relationships between OPN, bFGF levels and patients characteristics were examined using χ2 test, including treatment arm, age, smoking status, histology, clinical stage, performance status, weight loss and LDH. Effect of OPN and bFGF levels on progression-free survival (PFS) and overall survival (OS) were examined by multivariate analysis adjusted by treatment arm, smoking status, clinical stage, performance status, weight loss and LDH. Results: Seventy-one samples were obtained, including 32 specimens from the PC arm and 39 from the VGD arm. There were no significant relationships between either OPN or bFGF levels with patient characteristics. However, smokers tended to have higher OPN levels (p=0.083). In analysis of clinical outcome, low OPN levels correlated with better PFS (p<0.001), and high bFGF correlated with better OS (p=0.003). Conclusion: Consistent with findings from SWOG 0003, low OPN serum levels were significantly associated with a favorable prognosis in the JMTO LC 0004. Additionally, high bFGF levels were associated with improved survival. No significant financial relationships to disclose.
Abstract 15579: “Register and Roll”_A Novel Initiative to Improve First Door-to-Balloon Time in ST Elevation Myocardial Infarction
Authors: Sachin Kumar Amruthlal jain, Yousif Ismail, Michael Shaw, Shukri David, Patrick Alexander
Journal: Circulation (2012)

Objective: We sought to find the cause of delay in the transfer of patients presenting with an acute ST-segment myocardial infarction (STEMI) from non percutaneous coronary intervention (PCI) capab...
Comprehensive Transcriptome Profiling Reveals Multigene Signatures in Triple-Negative Breast Cancer
Authors: Yi-Rong Liu, Yi-Zhou Jiang, Xiao-En Xu, Xin Hu, Ke-Da Yu, Zhi-Ming Shao
Journal: Clinical Cancer Research (2016)

Abstract Purpose: By integrating expression profiles of mRNAs and long noncoding RNAs (lncRNA), we tried to develop and validate novel multigene signatures to facilitate individualized treatment of triple-negative breast cancer (TNBC) patients. Experimental Design: We analyzed 165 TNBC samples and 33 paired normal breast tissues using transcriptome microarrays. Tumor-specific mRNAs and lncRNAs were identified and correlated with patients' recurrence-free survival (RFS). Using Cox regression model, we built two multigene signatures incorporating mRNAs and lncRNAs. The prognostic and predictive accuracy of the signatures were tested in a training set of 165 TNBC patients and validated in other 101 TNBC patients. Results: We successfully developed an mRNA and an integrated mRNA–lncRNA signature based on eight mRNAs and two lncRNAs. In the training set, patients in the high-risk group were more likely to suffer from recurrent disease than patients in the low-risk group in both signatures [HR, 10.00; 95% confidence interval (CI), 2.53–39.47, P = 0.001; HR = 4.46, 95% CI, 1.34–14.91, P = 0.015 for integrated signature and mRNA signature, respectively). Results were validated in the validation set (P = 0.019 and 0.030, respectively). In addition, time-dependent receiver operating curve showed that the integrated mRNA–lncRNA signature had a better prognostic value than both the eight-mRNA-only signature and the clinicopathologic risk factors in both sets. We also found through interaction analysis that patients classified into the low-risk group by the integrated mRNA–lncRNA signature had a more favorable response to adjuvant taxane chemotherapy. Conclusions: The multigene signature we developed can accurately predict clinical outcome and benefit of taxane chemotherapy in TNBC patients. Clin Cancer Res; 22(7); 1653–62. ©2016 AACR.
총수담관 및 간내 종양으로 오인하기 쉬운 간질증 4예
Authors: 김용훈, 강구정, 권중혁
Journal: Clinical and Molecular Hepatology (2005)

Human fascioliasis is a zoonosis caused by Fasciola hepatica, and this is a trematode that infests cattle and sheep. Humans are accidental hosts in the life cycle of this parasite. People are infected by ingestion of the water or the raw aquatic vegetable
A phase I trial of intermittent high-dose α-interferon and dexamethasone in metastatic renal cell carcinoma
Authors: R. Amato, C. Meyers, J. Ellerhorst, L. Finn, R. Kilbourn, A. Sella, C. Logothetis
Journal: Annals of Oncology (1995)

Evidence exists that the toxic of alpha-interferon can be ameliorated by co-administration of dexamethasone without compromise of therapeutic efficacy. We therefore conducted a phase I trial to determine the maximum tolerated dose of intermittent interferon when combined with oral dexamethasone.Thirty patients with metastatic renal cell carcinoma were enrolled. The starting dose of interferon was 20 million IU/m2/day given as a subcutaneous injection days 1 to 4 of each 14 day cycle. Dose levels were escalated at increments of 5 million IU/m2. Dexamethasone 4 mg was administered orally every 6 hours during administration of high-dose interferon. Low-dose maintenance interferon, 3 million IU/m2/day, was administered without dose escalation on days 5 to 14 of each cycle.The maximum tolerated dose of intermittent high-dose interferon was 40 million IU/m2/day. The dose limiting toxicity was fatigue. EEG abnormalities developed in five patients and neuropsychiatric parameters deteriorated significantly in seventeen.We conclude that co-administration of dexamethasone improves the tolerance of intermittent high-dose interferon. The results of this trial may be useful in designing high-dose interferon regimens for renal cell carcinoma and other interferon-sensitive diseases.
What Would Mom Want?
Authors: Teddi Anderson Curry
Journal: JAMA (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Twists in the tale of impossible means
Authors: J. H. Loge
Journal: BMJ (2000)

Politics surrounding last winter's flu crisis NHS's fundamental problems must be solvedEditor-The NHS Confederation and the BMA have argued that the recent problems in dealing with emergency demand conceal more fundamental problems: the NHS has too little capacity run at too high a rate of use. 1 Running hospitals at the current rates of occupancy is not efficient.Bagust et al show that hospital occupancy of more than 85% will guarantee periodic bed crises and the cancellation of hospital admissions. 2 NHS occupancy information excludes patients who stay less than one day and therefore underestimates the true picture.In critical care a growing body of evidence suggests that there is insufficient spare capacity in the system.Many NHS staff have a ridiculous workload.They are required to cope with the chaotic results of high levels of admissions and occupancy and, in particular, the problem of patients on outlying wards.There is no time for staff to muster new resources, and nurses have had the parts of their work that allowed recuperation devolved to other staff.There is growing evi-dence that these problems affect outcomes and lead to staff seeking employment elsewhere, further exacerbating the pressure on those staff who remain.These problems have arisen because for 20 years the NHS has sought to do more work for less money.The measures of efficiency used by the government have in general paid little attention to the quality of the result, although there has been more of a move in this direction recently. 3The tight finances of the NHS have meant that improvements in efficiency can lead to a dilution of quality services, overstretching staff, being slow to adopt new medicines and technology, and failing to invest in major change that could improve the quality of what we do.Unfortunately, the latest planning guidance issued by the NHS Executive requires a further 3% increase in efficiency, which could make the problems worse. 4he absence of good baseline data means that it is difficult to prove that this will cause problems, and there is a danger of appearing to complain without evidence.We need to look at the way we measure performance and relate this more closely to broader measures than simple efficiency.
Breast cancer in Tripoli/Libya: 1990-2008.
Authors: M. M. Elhabbash, A. M. Alwindi
Journal: Journal of Clinical Oncology (2010)

e12052 Background: Breast cancer is the most frequently diagnosed cancer among women and second most frequent cause of cancer death. This study aims to to study epidemiology and biology of breast cancer in Tripoli over the past 19 years and to study survival and disease-free survival among these patients. Methods: Nonrandomized retrospective study in patients with breast cancer confirmed by biopsy, in onclogy clinic in central hospital and Tripoli Medical Center. 1,494 patients were included in this study in the period between Jan 1990till June 2008. Results: The age ranged between 20-70 years (mean 46.6 +12.6SD), median 46.5 years. 1.3% were male. 56.4% were premenopausal. 12.4% have positve family history of breast cancer. In years between 1990-1999, 39.5% of cases were stage I and II and 48.8% III and IV respectively, and in years between 2000 and 2008 48.5% were stage I and II and 41.5% III and IV respectively. 60% have involved lymph nodes. 87% of cancers were invasive duct carcinoma, 4.75% were invasive lobular carcinoma and 8.25% other histopathology. Hormone receptor status was studied after 2003 by immunohistochemistry, 54.3% were positive for estrogen receptors. 24% has HER2 overexpression. Most patients were treated by mastectomy (80%). Chemotherapy alone or chemotherapy with radiotherapy was given as adjuvant treatment. in years between 1990-1999, only 60% received anthracyclines based chemotherapy while in years 2000-2008, 87.6% received anthracycline based cheomtherapy. Tamoxifen was given to all patients who had positive receptors status or unknown status. During follow-up, out of 1,295 women on tamoxifen, 5 patients developed endometrial carcinoma. Regarding overall recurrence and survival rate, 5-year survival rate of patients diagnosed between 1990-1999 was 45.6% and disease-free survival was 37%. 5-year survival rate of patients diagnosed between 2000-2008 was 60.6% and disease-free survival was 50.3%. Conclusions: In the last 9 years, patients were diagnosed at earlier stages and better stratification of patients through the determination of hormone receptors and Neu status and the introduction of anthracyclines have contributed to better survival. No significant financial relationships to disclose.
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-α using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: A pilot study
Authors: M.P.N. Findlay, M.O. Leach, D. Cunningham, D.J. Collins, G.S. Payne, J. Glaholm, J.L. Mansi, V.R. McCready
Journal: Annals of Oncology (1993)
Phase III, randomized, double-blind study of elesclomol and paclitaxel versus paclitaxel alone in stage IV metastatic melanoma (MM)
Authors: A. Hauschild, A. M. Eggermont, E. Jacobson, S. J. O'Day
Journal: Journal of Clinical Oncology (2009)

LBA9012 The full, final text of this abstract will be available in Part II of the 2009 ASCO Annual Meeting Proceedings, distributed onsite at the Meeting on May 30, 2009, and as a supplement to the June 20, 2009, issue of the Journal of Clinical Oncology. [Table: see text]
The impact of an independent response evaluation committee (REC) using RECIST guidelines in a Four-Arm Cooperative Study (FACS) for advanced non-small cell lung cancer (NSCLC) in Japan
Authors: H. Watanabe, R. Ieki, K. Mori, Y. Takada, Y. Nishiwaki, Y. Ariyoshi, N. Saijo, M. Fukuoka
Journal: Journal of Clinical Oncology (2004)

7065 Background: From 44 hospitals in Japan, 602 patients (pts) with advanced NSCLC were registered in FACS. In 320 cases achieving more than 20% decrease in tumor size according to RECIST guidelines, a blinded peer review was prospectively performed by an independent REC. The purpose of the study was to investigate the impact of the independent REC using RECIST guidelines. Methods: Two diagnostic radiologists and two medical oncologists identified target and nontarget lesions from baseline medical images. Target lesions were measured by calipers. The concordance and discordance between the investigators and the REC were assessed. Using the Fisher's exact test, attempts were made to identify the factors for discordance, such as best overall response by investigators, alterations of target and nontarget lesions by REC and the number of pt accruals by institution. Results: Four pts were excluded due to insufficient data. Target and nontarget lesions documented by investigators were altered in 109 (34.5%) of 316 pts. The best overall response between investigators and REC are given in the table below. Of 209 PR pts, 52 pts were reclassified to SD and 3 pts reclassified to PD. Of 106 SD pts, 30 pts were reclassified to PR and 7 pts reclassified to PD. The Kappa value was 0.40 (95% CI (confidence intervals); 0.30 - 0.50) and the proportion of agreement was 70.9% (95% CI; 65.9 - 75.8). The number of PR cases reduced by 12.0% after review of the REC. There were no significant factors for discordance between investigators and REC. Conclusions: Despite both groups using RECIST guidelines, inter-observer variability between investigators and the independent REC existed. Investigators had a tendency to overestimate tumor response to chemotherapy, however, in SD cases judged by investigators, had an underestimation. No significant financial relationships to disclose.
ASCO Quality Oncology Practice Initiative: Harnessing the electronic medical record to provide decision support and to improve and measure quality oncology care.
Authors: R. Hurley, C. L. Jirik, D. L. Christensen-Johnson, M. M. Watry
Journal: Journal of Clinical Oncology (2010)

e16557 Background: ASCO's QOPI assesses the delivery of quality cancer care via semiannual data sumbission. Minnesota's HealthPartners Cancer Care Center, which uses the EPIC electronic medical record (EMR), has participated in ASCO QOPI by using manual chart review. We aimed to harness the EMR to coordinate and standardize multidisciplinary cancer care and facilitate data reporting. Methods: Using colorectal cancer as an example, we synthesized NCCN guidelines and ASCO QOPI core and colorectal cancer specific modules to develop a comprehensive colorectal cancer care model process that leverages the use of the EMR. Results: To develop this model, we collaborated with primary care MDs and specialists in gastroenterology, pathology, surgical and medical oncology within our medical group. Document flow sheets, standard dictation templates and order set tools were created to provide physician decision support, coordinate colonoscopic and pathology reporting and surgical, medical and radiation oncology consultation. For medical oncology, the tools facilitate the appropriate use of chemotherapy and radiation in the adjuvant and metastatic setting. These tools also prompt appropriate ASCO QOPI documentation. A general document flow sheet is utilized for initial oncology visits and separate modules can be added for adjuvant therapy, treatment of metastatic disease as well as follow up care and survivorship. The EPIC Synopsis tool allows a quick review of colorectal cancer pathway data. The pathway, itself, is readily accessible from the EMR by providers at all levels. A patient-oriented version is downloadable for patient education. Finally, information entered into the document flow sheet and entered via drop-down menus in the dictation template are reportable fields that allow easy retrieval of outcome measurements and facilitates ASCO QOPI reporting. Conclusions: The EMR can be adapted as a tool to coordinate and standardize care, provide desicion support and facilitate ASCO QOPI data submission. No significant financial relationships to disclose.
Karnofsky memorial lecture. The oncologic end game.
Authors: B A Chabner
Journal: Journal of Clinical Oncology (1986)

Article Tools Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.1986.4.5.626 Journal of Clinical Oncology - published online before print September 22, 2016 PMID: 3701386 Karnofsky memorial lecture. The oncologic end game. B A ChabnerxB A ChabnerSearch for articles by this author https://doi.org/10.1200/JCO.1986.4.5.626 First Page PDF © 1986 by American Society of Clinical Oncology
Stage 1 results from MDV3100-11: A 2-stage study of enzalutamide (ENZA), an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)
Authors: J. Cortes Castan, P. Schmid, A. Awada, H. Uppal, I.C. Tudor, M.E. Blaney, J.L. Steinberg, D.A. Yardley, C. Hudis, T.A. Traina
Journal: Annals of Oncology (2015)
Abstract 16393: Vascular Endothelial Function and Platelet Reactivity by Gender Differences Based on CYP2C19 Polymorphism are Associated With Cardiovascular Events Risk in Patients Undergoing Percutaneous Coronary Intervention (PCI)
Authors: Seiji Hokimoto, Tomonori Akasaka, Koichi Kaikita, Kazuko Nakagawa, Yuichiro Arima, Hisao Ogawa
Journal: Circulation (2013)

Background: Vascular endothelial function and CYP2C19 polymorphism are associated with clinical outcomes following PCI. However, the relation of gender differences to vascular endothelial function ...
Autoimmune Hepatitis - Overlap Syndrome (AH) occurring during imatinib therapy in a gastro-intestinal stromal tumor (GIST) patient
Authors: S. Aliberti, G. Grignani, P. Allione, G. Porrino, M. Fizzotti, F. Carnevale Schianca, D. Rota Scalabrini, G. Galatola, A. Pisacane, M. Aglietta
Journal: Journal of Clinical Oncology (2004)

9064 Background. AH is a chronic hepatitis of unknown etiology characterized by hyperglobulinemia, circulating autoantibodies (AA) and at least piecemeal necrosis on liver histology. GISTs are rare tumors in which the occurence of paraneoplastic disease have never been reported (National Library of Medicine). We describe the development of a chronic hepatitis in an Imatinib responsive GIST patient. Methods. A 65-year-old caucasian male presented with a GIST peritoneal spread. No signs of liver involvement were evident at CT and MRI. Liver function (aminotransferases, bilirubin, alkaline phosphatase and glutamyltranspeptidase) was normal. The patient was started on Imatinib 400 mg daily. A partial response was achieved after two months of treatment. At that time a progressive increase of aminotransferases (AST and ALT) without any other clinical sign of liver toxicity or GIST progression was detected. Liver infections, drug abuse and metabolic diseases were excluded. Autoantibodies were present therefore a liver biopsy was performed. Results. ANA and AMA-2 positivity was respectively weak and strong. Histology showed: interface hepatitis with piecemeal necrosis with lobular involvement, bridging necrosis and lymphocyte infiltrate. Prednisone (1mg/kg) prompted a progressive ALT reduction from 1056 U/L to normal value. Imatinib was concurrently restarted without any problem, leading to further GIST lesion reduction. Conclusions. A moderate increase of ALT is a well recognized and reversible Imatinib toxicity. In the occurence of increasing ALT value, regardless of Imatinib interruption, clinicians should be aware of AH. AH is responsive to steroid therapy and does not require to stop Imatinib for full recovery. No significant financial relationships to disclose.